Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
about
Risk factors for osteoporosis in inflammatory bowel disease patientsBone and TNF in rheumatoid arthritis: clinical implicationsGlucocorticoid-induced osteoporosisEffects of anti-tumor necrosis factor α agents on boneBiologic therapies and bone loss in rheumatoid arthritis.Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritisGeneralized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era.Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor useBone mineral density changes in patients with recent-onset rheumatoid arthritisOsteoimmunology and osteoporosis.The frequency of and risk factors for osteoporosis in Korean patients with rheumatoid arthritisBiologicals and bone loss.Glucocorticoids: bad or safe for the bones?Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseasesRheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.Bone effects of biologic drugs in rheumatoid arthritis.Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.Osteoporosis in inflammatory joint diseases.Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis.Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease.Bone loss in rheumatoid arthritis: systemic, periarticular, and focal.Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.Can bone loss in rheumatoid arthritis be prevented?Osteoporosis and osteoarthritis, rheumatoid arthritis and spondylarthropathies.Management of osteoporosis in rheumatoid arthritis patients.The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.Identification of small molecule inhibitors of RANKL and TNF signalling as anti-inflammatory and antiresorptive agents in mice.Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study.Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study.Changes in body composition after 2 years with rheumatoid arthritis.The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis.Bone mineral density in systemic lupus erythematosus women one year after rituximab therapy.Paradoxical elevation of serum TRACP5b levels despite increase in lumbar spine bone mineral density during anti-TNFα therapy in patients with inflammatory rheumatic disease: a 2-year prospective assessment of bone mass, bone metabolism, and the trabBiologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over.Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.Inflammatory diseases and bone fragility.Short-term daily teriparatide in patients with rheumatoid arthritis.Are glucocorticoids harmful to bone in early rheumatoid arthritis?TNFα regulates cortisol metabolism in vivo in patients with inflammatory arthritis
P2860
Q26776142-4D8B5F2B-6543-499E-97FA-F83B7379DCD3Q26777895-DB312CC3-B2BD-4CC5-B4C2-5802B200F816Q26778272-8CB65398-6799-48D4-AF63-19D356272E76Q26851274-982F55E4-0CC1-4D0C-98CD-84CA68D72699Q30243911-EC1E1218-4AF5-4379-A8A5-BCE34D05271AQ33648507-E340E6EC-F4A6-4A0E-BB8A-3E2FB9DEFBF7Q34168792-301CE9EA-9315-4E34-B9BF-56B2AC8B2F35Q34451418-7C415D33-3F8C-4855-ABE0-FF2E1D1DD10BQ35440451-53717D4F-AB10-4DB1-B65F-2CEE46871427Q35840701-5A5DED97-5CA1-43CD-87DD-0B3EF4CF5F41Q35934969-91392867-357C-4C00-87CA-39FA655840AAQ36111288-DFC1A742-CFD7-4C03-92D4-71F210AF909CQ36246088-886B6B94-C016-418D-8FD6-771B589AD2CAQ36781280-34496434-93FA-4535-ABBF-D5E0B637BDDFQ36839197-4C0A09A6-688F-40A3-A57C-95702A261395Q36995387-79383F7C-FB0D-42FC-B95F-E8039D8D4A60Q37051820-BF2D3611-F4ED-4975-9048-F147EA0B77D8Q37765505-E37BA4C3-23BD-4D17-BB68-305645C4A045Q37801555-4E31C0B8-8BDD-4984-B1EE-000A4AE1FFD8Q37869193-0E985856-1B4F-4DC9-B590-B7FBB05C7A94Q38004957-BEA4C511-A867-4157-9D93-209AD18DD0F4Q38041419-28DBFE36-E8E3-4531-B36E-E5F0C0B651D1Q38115190-644DDFB5-1213-44E3-9BC0-289899566A4EQ38148506-4A9B9240-1DBC-4AD6-BD36-533BAB4E5747Q38334318-7EC1BB6F-65C6-42C2-81DC-D6072E5DE9D6Q38831693-56D2C22A-19D7-41B7-8E5D-7FF50A440362Q39085876-C7A5A25A-B2C8-4464-AACB-F13B84A6861EQ40079134-FCD8BF98-C1AB-4B21-83CA-94177FB1F61EQ42669655-0207EA8E-FDDF-405E-A20D-872E2F6AE24AQ44174557-4000CAAB-6CFC-4367-8C3D-7F1969DBFD7DQ44793969-033D8517-1B22-4DAB-A164-E4DAD087424EQ44794499-BDC6F5D2-B6E7-458F-B5C2-9B3041530329Q45832844-E3D57AF8-F854-4011-96B1-88EFF20BC08AQ46155482-09128E44-9313-4D6F-8396-45561D57F462Q46671185-ECD79B9E-2C9C-4979-99B6-E41DDA5159D8Q47975714-84D7596A-4F9A-4735-9DE7-066CC70C86EDQ48694023-219C3ADA-8633-48FA-9671-911126D0E156Q51741238-295FC85B-867B-4923-924B-72EDF9280CF5Q57231864-42FF38CC-F09F-4094-9043-8CFDFE63F973
P2860
Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Bone mineral density in rheuma ...... therapy: arrest of bone loss.
@ast
Bone mineral density in rheuma ...... therapy: arrest of bone loss.
@en
Bone mineral density in rheuma ...... therapy: arrest of bone loss.
@nl
type
label
Bone mineral density in rheuma ...... therapy: arrest of bone loss.
@ast
Bone mineral density in rheuma ...... therapy: arrest of bone loss.
@en
Bone mineral density in rheuma ...... therapy: arrest of bone loss.
@nl
prefLabel
Bone mineral density in rheuma ...... therapy: arrest of bone loss.
@ast
Bone mineral density in rheuma ...... therapy: arrest of bone loss.
@en
Bone mineral density in rheuma ...... therapy: arrest of bone loss.
@nl
P2093
P2860
P356
P1476
Bone mineral density in rheuma ...... therapy: arrest of bone loss.
@en
P2093
B L F van Eck-Smit
C A Wijbrandts
D M Gerlag
M G W Dijkgraaf
P2860
P304
P356
10.1136/ARD.2008.091611
P407
P577
2008-04-13T00:00:00Z